CytomX Therapeutics (NASDAQ:CTMX) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Friday.

A number of other brokerages also recently commented on CTMX. Cowen reissued an “outperform” rating on shares of CytomX Therapeutics in a research report on Thursday, October 5th. ValuEngine downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Nomura lifted their target price on shares of CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a report on Wednesday, October 4th. Cantor Fitzgerald began coverage on shares of CytomX Therapeutics in a report on Monday, October 23rd. They set an “overweight” rating and a $35.00 target price for the company. Finally, Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a report on Monday, October 16th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. CytomX Therapeutics currently has a consensus rating of “Hold” and an average price target of $31.88.

Shares of CytomX Therapeutics (CTMX) traded down $0.09 on Friday, hitting $21.57. 1,321,403 shares of the stock were exchanged, compared to its average volume of 374,506. CytomX Therapeutics has a 52 week low of $10.40 and a 52 week high of $24.67.

In other CytomX Therapeutics news, CEO Sean A. Mccarthy sold 19,120 shares of CytomX Therapeutics stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $24.13, for a total value of $461,365.60. Following the completion of the sale, the chief executive officer now owns 23,365 shares in the company, valued at approximately $563,797.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $18.10, for a total transaction of $45,250.00. The disclosure for this sale can be found here. Insiders sold a total of 173,009 shares of company stock valued at $3,835,417 in the last quarter. Corporate insiders own 4.70% of the company’s stock.

Institutional investors have recently modified their holdings of the business. New York State Common Retirement Fund raised its position in shares of CytomX Therapeutics by 48.8% in the 2nd quarter. New York State Common Retirement Fund now owns 31,100 shares of the biotechnology company’s stock valued at $482,000 after buying an additional 10,199 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of CytomX Therapeutics in the 1st quarter valued at approximately $190,000. Trexquant Investment LP acquired a new position in shares of CytomX Therapeutics in the 3rd quarter valued at approximately $474,000. California State Teachers Retirement System raised its position in shares of CytomX Therapeutics by 27.8% in the 2nd quarter. California State Teachers Retirement System now owns 51,430 shares of the biotechnology company’s stock valued at $797,000 after buying an additional 11,200 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its position in shares of CytomX Therapeutics by 183.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 169,552 shares of the biotechnology company’s stock valued at $2,628,000 after buying an additional 109,791 shares in the last quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “CytomX Therapeutics (CTMX) Upgraded at BidaskClub” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/12/16/cytomx-therapeutics-ctmx-upgraded-at-bidaskclub.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.